Renal Protection and Antihypertensive Drugs

United States Renal Data System 1997 Annual Report. Incidence and prevalence of ESRD. Am J Kidney Dis 1997; 30 Suppl. 2: S40-53 Vanrenterghen Y, Jones EH. Report on management of renal failure in Europe, XXVI, 1995: report based on the Centre Questionnaire. The ERA-EDTA Registry. Nephrol Dial Transplant 1996; 11 Suppl. 7: 28–32 Simeon G, Bakris GL. Socioeconomic impact of diabetic nephropathy: can we improve the outcome? J Hypertens 1997; 15 Suppl. 2: S77–82 Parving H-H. Microalbuminuria in essential hypertension and diabetes mellitus. J Hypertens 1996; 14 Suppl. 2: S89–94 Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997; 51: 2–15 Baba T, Neugebauer S, Watanabe T. Diabetic nephropathy: its relationship to hypertension and means of pharmacological intervention. Drugs 1997; 54: 197–234 Goa KL, Haria M, Wilde MI. Lisinopril: a review of its pharmacology and use in the management of the complications of diabetes mellitus. Drugs 1997; 53: 1081–105 Rosansky SJ, Hoover DR, King L, et al. The association of blood pressure levels and change in renal function in hypertensive and non hypertensive subjects. Arch Intern Med 1990; 150: 2073–6 Perneger TV, Nieto J, Whelton PK, et al. A prospective study of blood pressure and serum creatinine: results from the ‘Clue’ study and the ARIC study. JAMA 1993; 269: 488–93 Mountokalakis TD. The renal consequences of arterial hypertension. Kidney Int 1997; 51: 1639–53 Zucchelli P, Zuccalà A. The kidney as a victim of essential hypertension. J Nephrol 1997; 10: 203–6 Epstein M. Diabetes and hypertension: bad companions. J Hypertens 1997; 15 Suppl. 2: S55–62 Oldrizzi L, Rugiu C, Maschio G. Hypertension and progression of renal failure in patients on protein-restricted diet. Contrib Nephrol 1987; 54: 134–43 Brazy PC, Stead WW, Fitzwilliam JF. Progression of renal insufficiency: role of blood pressure. Kidney Int 1989; 35: 670–4 Mogensen CE. Management of the diabetic patient with elevated blood pressure or renal disease. Early screening and treatment programs: albuminuria and blood pressure. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis and management. 2nd ed. New York: Raven Press, 1995: 2335–65 Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13–8 Maschio G, Marcantoni C. Progressive renal damage in essential hypertension. High Blood Press 1997; 6: 65–7 Perneger TV, Whelton PK, Klag MJ. History of hypertension in patients treated for end-stage renal disease. J Hypertens 1997; 15: 451–6 Walker WG. Hypertension-related renal injury: a major contributor to end-stage renal disease. Am J Kidney Dis 1993; 22: 164–73 Salvetti A, Giovannetti R, Arrighi P, et al. What effect does blood pressure control have on the progression toward renal failure? Am J Kidney Dis 1993; 21 Suppl. 3: 10–5 Epstein ME, Bakris G. Newer approaches to antihypertensive therapy. Arch Intern Med 1996; 156: 1969–78 Epstein M. The benefits of ACE inhibitors and calcium antagonists in slowing progressive renal failure: focus on fixed-dose combination antihypertensive therapy. Ren Fail 1996; 18(6): 813–32 Rodicio JL. Does antihypertensive therapy protect the kidney in essential hypertension? J Hypertens 1996; 14 Suppl. 2: S69–76 van Hooft IMS, Grobbee DE, Derkx FHM, et al. Renal hemodynamics and the renin-angiotensin-aldosterone system in normotensive subjects with hypertensive and normotensive parents. N Engl J Med 1991; 324: 1305–11 Pedrinelli R, Magagna A, Arzilli F, et al. Influence of indomethacin on the natriuretic and renin-stimulating effect of bumetanide in essential hypertension. Clin Pharmacol Ther 1980; 28: 722–31 Benstein JA, Dworkin LD. Renal vascular effects of calcium channel blockers in hypertension. Am J Hypertens 1990; 3: S305–12 Salvetti A. Newer ACE inhibitors: a look at the future. Drugs 1990; 40: 800–28 Burnier M, Brunner HR. Angiotensin II receptor antagonists and the kidney. Curr Opin Nephrol Hypertens 1994; 3: 537–45 deLeeuw PW, Birkenhäger WH. Renal hemodynamics and glomerular filtration in essential hypertension: effects of treatment. In: Hansson L, Birkenhäger WH, editors. Hand book of hypertension: assessment of hypertensive organ damage. Amsterdam: Elsevier Science, 1997: 345–63 Hoelscher DD, Weir MR, Bakris GL. Hypertension in diabetic patients: an update of interventional studies to preserve renal function. J Clin Pharmacol 1995; 35: 73–80 Meyer TW, Baboolal K, Brenner BM. Nephron adaptation to renal injury. In: Brenner BM, editor. The kidney. Philadelphia: WB Saunders Company, 1996: 2011–48 Griffin KA, Picken MM, Bidani AK. Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J Clin Invest 1995; 96: 793–800 Ichikawa I, Harris RC. Angiotensin actions in the kidney: renewed insight into the old hormone. Kidney Int 1991; 40: 583–96 Geza S, Abraham G. Angiotensin II administration as an experimental model of hypertension. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis and management. 2nd ed. New York: Raven Press, 1995: 1423–35 Hemmelder MH, de Zeeuw D, Gansevoort RT, et al. Blood pressure reduction initiates the antiproteinuric effect of ACE inhibition. Kidney Int 1996; 49: 174–80 Yoshida Y, Fogo A, Ichikawa I. Glomerular hemodynamic changes versus hypertrophy in experimental glomerular sclerosis. Kidney Int 1989; 35: 654–60 Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77: 1993–2000 Zatz R, Dunn BR, Meyer TW, et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925–30 Dworkin LD, Benstein JA, Parker M, et al. Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int 1993; 43: 808–14 Hollenberg NK, Raij L. Angiotensin-converting enzyme inhibition and renal protection. An assessment of implications for therapy. Arch Intern Med 1993; 153: 2426–35 Imanishi M, Yoshioka K, Okumura M, et al. Mechanism of decreased albuminuria caused by angiotensin converting enzyme inhibitor in early diabetic nephropathy. Kidney Int 1997; 52 Suppl. 63: S198–200 Mimran A, Insua A, Ribstein J, et al. Contrasting effects of captopril and nifedipine in normotensive patients with diabetic nephropathy. J Hypertens 1988; 6: 919–23 Kon V, Fogo A, Ichikawa I, et al. Bradikinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 1993; 44: 545–50 Komers R, Cooper ME. Acute renal hemodynamic effects of ACE inhibition in diabetic hyperfiltration: role of kinins. Am J Physiol 1995; 37: F588–94 Lafayette RA, Mayer G, Park SK, et al. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992; 90: 766–71 Pollock DM, Divish BJ, Polakowski JS, et al. Angiotensin II receptor blockade improves renal function in rats with reduced renal mass. J Pharmacol Exp Ther 1993; 267: 657–63 Tarif N, Bakris GL. Angiotensin II receptor blockade and progression of nondiabetic-mediated renal disease. Kidney Int 1997; 52 Suppl. 63: S67–70 Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45: 861–7 Remuzzi A, Perticucci E, Ruggenenti P, et al. Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int 1991; 39: 1267–73 Hansen HP, Rossing P, Tarnow L, et al. Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. Kidney Int 1995; 47: 1726–31 Ichikawa I. Will angiotensin II receptor antagonists be renoprotective in humans? Kidney Int 1996; 50: 684–92 Apperloo AJ, de Zeeuw D, de Jong PE. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997; 51: 793–7 Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study. Ann Intern Med 1995; 123: 754–62 Carmines PK, Navar LG. Disparate effects of Ca channel blockade on afferent and efferent arteriolar responses to Ang II. Am J Physiol 1989; 256: F1015–20 Brown SA, Walton CL, Crawford P, et al. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int 1993; 43: 1210–8 Anderson S. Renal hemodynamic effects of calcium antagonists in rats with reduced renal mass. Hypertension 1991; 17: 288–95 Tarif N, Bakris GL. Preservation of renal function: the spectrum of effects by calcium-channel blockers. Nephrol Dial Transplant 1997; 12: 2244–50 Murakami K, Kimura G, Imanishi M, et al. Effect of manidipine, a new calcium antagonist, on intrarenal hemodynamics in essential hypertension. Blood Press 1992; 1 Suppl. 3: 114–8 ter Wee PM, De Micheli AG, Epstein M. Effects of calcium antagonists on renal hemodynamics and progression of non-diabetic chronic renal disease. Arch Intern Med 1994; 154: 1185–202 Amann K, Irzyniec T, Mall G, et al. The effect of enalapril on glomerular growth and glomerular lesions after subtotal nephrectomy in the rat: a stereological analysis. J Hypertens 1993; 11: 969–75 Remuzzi G, Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 1990; 38: 384–94 Mayer G, Lafayette RA, Oliver J, et al. Effects of angiotensin II receptor blockade on remnant glomerular permselectivity. Kidney Int 1993; 43: 346–53 Iseki K, Ikemiya Y, Fukiyama K. Risk factors of end-stage renal disease and serum creatinine in a community-based mass screening. Kidney Int 1997; 51: 850–4 Williams JD, Coles GA. Proteinuria-A direct cause of renal morbidity? Kidney Int 1994; 45: 443–50 Mogensen CE. Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 1971; 31: 673–89 Viberti GC, Hill RD, Jarrett RJ, et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982; I: 1430–42 Hunt LP, Short CD, Mallick NP. Prognostic indicators in patients presenting with the nephrotic syndrome. Kidney Int 1988; 34: 382–8 Williams PS, Fass G, Bone JM. Renal pathology and proteinuria determine progression in untreated mild/moderate chronic renal failure. Q J Med 1988; 252: 343–54 Jungers P, Hannedouche T, Itakura Y, et al. Progression rate to end-stage renal failure in non-diabetic kidney disease: a multivariate analysis of determinant factors. Nephrol Dial Transplant 1995; 10: 1353–60 Locatelli F, Marcelli D, Comelli M, et al. Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Nephrol Dial Transplant 1996; 11: 461–7 Locatelli F, Manzoni C, Marcelli D. Factors affecting progression of renal insufficiency. Miner Electrolyte Metab 1997; 23: 301–5 Ruggenenti P, Perna A, Mosconi L, et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. Kidney Int 1997; 52 Suppl. 63: S54–7 Praga M, Hernandez E, Montoyo C, et al. Long-term beneficial effects of angiotensin-converting-enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 1992; 20: 240–8 Gansevoort RT, de Zeeuw D, de Jong PE. Long-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in nondiabetic renal disease. Am J Kidney Dis 1993; 22: 202–6 Apperloo AJ, deZeeuw D, de Jong PE. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with nondiabetic renal disease. Kidney Int 1994; 45 Suppl. 45: S174–8 Rossing P, Hommel E, Smidt UM, et al. Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int 1994; 45 Suppl. 45: S145–9 Kamper A-L, Strandgaard S, Leyssac PP. Late outcome of a controlled trial of enalapril treatment in progressive chronic renal failure: hard end-points and influence of proteinuria. Nephrol Dial Transplant 1995; 10: 1182–8 Barnas U, Schmidt A, Haas M, et al. The effects of prolonged angiotensin-converting enzyme inhibition on excretory kidney function and proteinuria in renal allograft recipients with chronic progressive transplant failure. Nephrol Dial Transplant 1996; 11: 1822–4 Kasiske BL; Kalil RSN, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129–38 Weidmann P, Böehlen LM, de Courten M. Effects of different antihypertensive drugs on human diabetic proteinuria. Nephrol Dial Transplant 1993; 8: 582–4 Böhlen L, deCourten M, Weidmann P. Comparative study of the effect of ACE inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994; 7: S84–92 Maki DD, Ma JZ, Louis TA, et al. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995; 155: 1073–80 Weidmann P, Schneider M, Böhlen L. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated meta-analysis. Nephrol Dial Transplant 1995; 10 Suppl. 9: 39–45 Gansevoort RT, Sluiter WJ, Hemmelder MH, et al. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995; 10: 1963–74 Morelli E, Loon N, Meyer T, et al. Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 1990; 39: 76–82 Remuzzi A, Ruggenenti P, Mosconi L, et al. Effect of low-dose enalapril on glomerular size-selectivity in human diabetic nephropathy. J Nephrol 1993; 6: 36–43 Taguma Y, Kitamoto Y, Futaki G, et al. Effect of Captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 1985; 313: 1617–20 Hommel E, Parving H-H, Mathiesen E, et al. Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. BMJ 1986; 293: 467–70 Heeg JE, de Jong PE, van der Hem GK, et al. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989; 36: 272–9 Kohara K, Mikami H, Okuda N, et al. Angiotensin blockade and progression of renal damage in the spontaneously hypertensive rat. Hypertension 1993; 21: 975–9 Fornes P, Richer C, Vacher E, et al. Losartan’s protective effect in stoke-prone spontaneously hypertensive rats persist durably after treatment withdrawal. J Cardiovasc Pharmacol 1993; 22(2): 305–13 Tanaka R, Kon V, Yoshioka T, et al. Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms. Kidney Int 1994; 45: 537–43 Hutchinson BW, Webster SK. Effect of Ang II receptor antagonist on albuminuria and renal function in passive Heimann nephritis. Am J Physiol 1992; 263: F311–8 Zoccali C, Valvo E, Russo D, et al. Antiproteinuric effect of losartan in patients with chronic renal diseases. Nephrol Dial Transplant 1997; 12: 234–5 Zoja C, Corna D, Facchinetti D, et al. Combining ACE inhibition and angiotensin II receptor blocking stop renal disease progression in experimental membranous nephropathy [abstract]. J Am Soc Nephrol 1995; 6: 860 Bakris GL. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 1990; 112: 707–8 Bakris GL, Copley JB, Vicknair N, et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996, 50: 1641–50 Rossing P, Tarnow L, Boelskifte S, et al. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes 1997; 46: 481–7 Salvetti A, Innocenti PF, Iardella M, et al. Captopril and nifedipine interactions in the treatment of essential hypertensive: a crossover study. J Hypertens 1987; 5 Suppl. 4: S139–42 Kanayama N, Tsujimura R, She L, et al. Cold-induced stress stimulates the sympathetic nervous system, acusing hypertension and proteinuria in rats. J Hypertens 1997; 15: 383–9 Poulsen PL, Ebbehøj E, Hansen KW, et al. 24-h blood pressure and autonomic function is related to albumin excretion within the normoalbuminuric range in IDDM patients. Diabetologia 1997; 40: 718–25 Mølgaard H, Christensen PD, Sørensen KE, et al. Association of 24-h cardiac parasympathetic activity and degree of nephropathy in IDDM patients. Diabetes 1992; 41: 812–7 Weinrauch LA, Kennedy FP, Geason RE, et al. Relationship between autonomic function and progression of renal disease in diabetic proteinuria. Am J Hypertens 1998; 11: 302–8 Fogari R, Zoppi A, Lusardi P, et al. Long term effects of ramipril and nitrendipine on albuminuria in diabetic hypertensive patients with impaired renal function [abstract]. J Hypertens 1996; 14 Suppl. 1: S193 Lusardi P, Corradi L, Pasotti C, et al. Effects of amlodopine vs fosinopril on microalbuminuria in elderly hypertensive patients with type II diabetes [abstract]. J Hypertens 1996; 14 Suppl. 1: S193 Stornello M, Valvo EV, Scapellato L. Hemodynamic, renal, and humoral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor captopril in hypertensive type II diabetic patients with nephropathy. J Cardiovasc Pharmacol 1989; 14: 851–5 Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int 1992; 41: 912–9 Fogari R, Zoppi A, Mugellini A, et al. Effect of benazepril plus amlodipine vs benazepril alone on urinary albumin excretion in hypertensive patients with type II diabetes and microalbuminuria. Clin Drug Invest 1997; 13 Suppl. 1: S50–5 Raij L. Effects of ACE inhibitors and calcium channel blockers on the development of glomerular sclerosis in models of renal damage. Nephrol Dial Transplant 1995; 10 Suppl. 9: S23–7 Luscher TF, Vanhoutte PM. The endothelium: modulator of cardiovascular function. Boca Raton: CRC Press, 1990 Raij L, Baylis C. Glomerular actions of nitric oxide. Kidney Int 1995; 48: 20–32 Mattei P, Virdis A, Ghiadoni L, et al. Endothelial function in hypertension. J Nephrol 1997; 10: 193–8 Rabelink TJ, Koomans HA. Endothelial function and the kidney: an emerging target for cardiovascular therapy. Drugs 1997; 53 Suppl. 1: 11–9 Remuzzi G, Benigni A. Progression of proteinuric diabetic and nondiabetic renal diseases: a possible role for renal endothelin. Kidney Int 1997; 51 Suppl. 58: S66–8 Mimran A, Ribstein J, DuCailar G. Contrasting effect of anti-hypertensive treatment on the renal response to L-Arginine. Hypertension 1995; 26: 937–41 Higashi Y, Oshima T, Ozono R, et al. Effects of L-arginine infusion on renal hemodynamics in patients with mild essential hypertension. Hypertension 1995; 25: 898–902 Higashi Y, Oshima T, Watanabe M, et al. Renal response to L-arginine in salt-sensitive patients with essential hypertension. Hypertension 1996; 27: 643–8 Taddei S, Virdis A, Ghiadoni L, et al. Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in essential hypertensive patients. J Hypertens 1998; 16: 447–56 Dijkhorst-Oei LT, Rabelink TJ, Boer P, et al. Nifedipine attenuates systemic and renal vasoconstriction during nitric oxide inhibition in humans. Hypertension 1997; 29: 1192–8 Taddei S, Virdis A, Ghiadoni L, et al. Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients. Hypertension 1997; 30; 1606–12 Taddei S, Virdis A, Ghiadoni L, et al. Nifedipine enhances endothelimu-dependent relaxation and ihnibits contractions to endothelin-1 and phenilephrine in human hypertension [abstract]. Circulation 1997; 96: 4275 Madeddu P, Yang X, Anania V, et al. Efficacy of nifedipine to prevent systemic and renal vasoconstrictor effects of endothelin. Am J Physiol 1990; 259: F304–11 Takahashi K, Katoh T, Fukunaga M, et al. Studies on the glomerular microcirculatory actions of manidipine and its modulation of the systemic and renal effects of endotehlin. Am Heart J 1993; 125: 609–19 Rabelink TJ, Kaasjager KAH, Boer P, et al. Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology. Kidney Int 1994; 46: 376–81 Consensus Development Conference on the treatment of hypertension in diabetes. Treatment of hypertension in diabetes. Diabetes Care 1993; 16: 1394–401 World Health Organization/International Society of Hypertension. Guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens 1993; 11: 905–18 World Health Organization Expert Committee. Hypertension control. Geneva: World Health Organization, 1996 The Sixth Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413–46 Ruilope LM, Garcia-Robles R. How far should blood pressure be reduced in diabetic hypertensive patients? J Hypertens 1997; 15 Suppl. 2: S63–5 Rodby RA, Rohde R, Evans J, et al. The study of the effect of intensity of blood pressure management on the progression of type 1 diabetic nephropathy: study design and baseline patient characteristics. J Am Soc Nephrol 1995; 5: 1775–81 Bain R, Rohde R, Hunsicker LG, et al. A controlled clinical trial of angiotensin-converting enzyme inhibition in type 1 diabetic nephropathy: study design and patients chracteristics. J Am Soc Nephrol 1992; 3: S97–103 Schrier RW, Estacio RO, Jeffers B. Appropriate blood pressure control in NIDDM (ABCD) trial. Diabetologia 1996; 39: 1646–54 Mehler PS, Jeffers BW, Estacio R, et al. Associations of hypertension and complications in non-insulin-dependent diabetes mellitus. Am J Hypertens 1997; 10: 152–61 Hansson L, Zanchetti A. The Hypertension Optimal Treatment (HOT) study-patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Press 1994; 3: 322–7 Jamerson K. The effect of blood pressure reduction on end stage renal disease. Am J Hypertens 1996; 9: S60–4 Oldrizzi L, Rugiu C, De Biase V, et al. The place of hypertension among the risk factors for renal function in chronic renal failure. Am J Kidney Dis 1993; 21 Suppl. 2: 119–23 Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330: 877–84 Levey AS, Bosch JP, Coggins CH, et al. Effects of diet and antihypertensive therapy on creatinine clearance and serum creatinine concentration in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol 1996; 7: 556–65 Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997; 51: 1908–19 Lazarus JM, Bourgoignie JJ, Buckalew VM, The Modification of Diet in Renal Disease Study Group, et al. Achievement and safety of a low blood pressure goal in chronic renal disease. Hypertension 1997; 29: 641–50 Hebert LA, Kusek JW, Greene T, et al. Effects of blood pressure control on progressive renal disease in blacks and whites. Hypertension 1997; 30: 428–35 Wright JT, Kusec JW, Toto RD, et al. Design and baseline characteristics of participants in the African-American Study of Kidney disease and hypertension (AASK) Pilot study. Control Clin Trials 1996; 17 Suppl. 4: S3–16 The EUCLID study group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787–92 Chan JCN, Cockram CS, Nicholls MG, et al. Comparison of enalapril and nifedipine in treating non-insulin-dependent diabetes associated with hypertension: one year analysis. BMJ 1992; 305: 981–5 Lacourcière Y, Nadeau A, Poirier L, et al. Captopril or conventional therapy in hypertensive type II diabetics: three-year analysis. Hypertension 1993; 21: 786–94 Velussi M, Brocco E, Frigato F, et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996; 45: 216–22 Mathiesen ER, Hommel E, Giese J, et al. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 1991; 303–7 Mathiesen ER, Hommel E, Smith U, et al. Efficacy of captopril in normotensive diabetic patients with microalbuminuria 8 years follow up [abstract]. Diabetologia 1995; 38: A46 Crepaldi G, Carta Q, DeFerrari G, et al. Effects of lisinopril and nifedipine on the progression to overt proteinuria in insulin-dependent diabetic patients with incipient nephropathy and normal blood pressure. Diabetes Care 1998; 21(1): 104–10 Nielsen S, Schmitz A, Rehling M, et al. Systolic blood pressure relates to the rate of decline of glomerular filtration rate in type II diabetes. Diabetes Care 1993; 16: 1427–32 Bilo H, Kluitman E, van Ballegooie E, et al. Long term use of captopril or nifedipine in normotensive microalbuminuric patients with insulin-dependent diabetes mellitus. Diabetes Res 1993; 23: 115–2 Viberti G, Mogensen CE, Groop LC, et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994; 271: 275–9 Schnack C, Capek M, Banyai M, et al. Long-term treatment with nifedipine reduces urinary albumin excretion and glomerular filtration rate in normotensive type 1 diabetic patients with microalbuminuria. Acta Diabetol 1994; 31: 14–8 Laffel LMB, McGill JB, Gans DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 1995: 99: 497–593 The Microalbuminuria Captopril Study Group. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 1996; 39: 587–93 Hallab M, Gallois Y, Chatellier G, et al. Comparison of reduction in microalbuminuria by enlapril and hydrochlorothiazide in normotensive patients with insulin dependent diabetes. BMJ 1993; 306: 175–82 Salvetti A, Virdis A, Taddei S, et al. Trough: peak ratio of nifedipine gastrointestinal therapeutic system and nifedipine retard in essential hypertensive patients: an Italian multicentre study. J Hypertens 1996; 14: 661–7 Fioretto P, Frigato F, Velussi M, et al. Effects of angiotensin converting enzyme inhibitors and calcium antagonists on atrial natriuretic peptide release and action and on albumin excretion rate in hypertensive insulin-dependent diabetic patients. Am J Hypertens 1992; 5: 837–46 Ravid M, Savin H, Jutrin I, et al. Long-term effect of ACE inhibition on development of nephropathy in diabetes mellitus type II. Kidney Int 1994; 45 Suppl. 45: S161–4 Baba T, Murabayashi S, Takebe K. Comparison of the renal effects of angiotensin-converting enzyme inhibitor and calcium antagonist in hypertensive type 2 (non-insulin-dependent) diabetic patients with microalbuminuria: a randomised controlled trial. Diabetologia 1989; 32: 40–4 Ruggenenti P, Mosconi L, Bianchi L, et al. Long-term treatment with either enalapril or nitrendipine stabilizes albuminuria and increases glomerular filtration rate in non-insulin-dependent diabetic patients. Am J Kidney Dis 1994; 24: 753–61 Agardh CD, Garcia-Puig J, Charbonnel B, et al. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996; 10: 185–92 Mosconi L, Ruggenenti P, Perna A, et al. Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes. Kidney Int 1996; 49 Suppl. 55: S91–3 Piñol C, Cobos A, Cases A, et al. Nitrendipine and enalapril in the treatment of diabetic hypertensive patients with microalbuminuria. Kidney Int 1996; 49 Suppl. 55: S85–7 Marre M, Chatellier G, Leblanc H, et al. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ 1988; 297: 1092–5 O’Donnel MJ, Rowe BR, Lawson N, et al. Placebo-controlled trial of lisinopril in normotensive diabetic patients with incipient nephropathy. J Hum Hypertens 1993; 7: 327–32 Bretzel RG, Bollen CC, Maeser E, et al. Nephroprotective effects of nitrendipine in hypertensive type I and type II diabetic patients. Am J Kidney Dis 1993; 21 Suppl. 3: 53–64 Melbourne Diabetic Nephropathy Study Group. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ 1991; 302: 210–6 Lebovitz HE, Wiegmann TB, Cnaan A, et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl 1994; 45: S150–5 Stornello M, Valvo EV, Vasquez E, et al. Systemic and renal effects of chronic angiotensin converting enzyme inhibition with captopril in hypertensive diabetic patients. J Hypertens Suppl 1989; 7(7): S65–7 Valvo E, Bedogna V, Casagrande P, et al. Captopril in patients with type II diabetes and renal insufficiency: systemic and renal hemodynamic alterations. Am J Med 1988; 85: 344–8 Parving H-H, Hommel E, Nielsen MD, et al. Effect of captopril on blood pressure and kidney function in normotensive insulin-dependent diabetics with nephropathy. BMJ 1989; 299: 533–6 Holdaas H, Hartmann A, Lien MG, et al. Contrasting effects of lisinopril and nifedipine on albuminuria and tubular transport functions in insulin dependent diabetics with nephropathy. J Intern Med 1991; 229: 163–70 Björck S, Mulec H, Johnsen SA, et al. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992; 304: 339–43 De Cesaris R, Ranieri G, Filitti V, et al. Effects of atenolol and enalapril on kidney function in hypertensive diabetic patients. J Cardiovasc Pharmacol 1993; 22: 208–14 Elving LD, Wetzeis JFM, van Lier HJJ, et al. Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Diabetologia 1994; 37: 604–9 Norgaard K, Jensen T, Christensen P, et al. A comparison of spirapril and isradipine in patients with diabetic nephropathy and hypertension. Blood Press 1993; 2: 301–8 Stornello M, Valvo EV, Scapellato L. Persistent albuminuria in normotensive non-insulin-dependent (type II) diabetic patients: comparative effects of angiotensin-converting enzyme inhibitors and β-adrenoceptor blockers. Clin Sci 1992; 82: 19–23 Stornello M, Valvo EV, Scapellato L. Comparative effects of enalapril, atenolol and chlorthalidone on blood pressure and kidney function of diabetic patients affected by arterial hypertension and persistent proteinuria. Nephron 1991; 58: 52–7 Demarie BK, Bakris GL. Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Intern Med 1990; 113: 987–8 Bakris GL, Smith A. Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med 1996; 125: 210–4 Bauer JH, Reams GP, Hewett J, et al. A randomized, double-blind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy. Am J Kidney Dis 1992; 20: 443–57 Ferder L, Daccordi H, Martello M, et al. Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients. Hypertension 1992; 19 Suppl. 2: 237–42 Nielsen FS, Rossing P, Gall MA, et al. Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1994; 43: 1108–13 Liou H-H, Huang TP, Campese VM. Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes and with non-diabetic renal disease. Nephron 1995; 69: 41–8 Fogari R, Zoppi A, Pasotti C, et al. Comparative effects of ramipril and nitrendipine on albuminuria in hypertensive patients with non-insulin-dependent diabetes mellitus and impaired renal function. J Hum Hypertens 1995; 9: 131–5 Nielsen FS, Rossing P, Gall MA et al. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997; 46: 1182–8 Bakris GL, Mangrum A, Copley JB, et al. Effect of calcium channel or β-blockade on the progression of diabetic nephropathy in african americans. Hypertension 1997; 29: 744–50 Stornello M, Valvo EV, Puglia N, et al. Angiotensin-converting enzyme inhibition with a low dose of enalapril in normotensive diabetics with persistent proteinuria. J Hypertens 1988; 6 Suppl. 4: S464–6 Taft JL, Nolan CJ, Yeung SP, et al. Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes 1994; 43: 1046–51 O’Donnel MJ, Rowe BR, Lawson N, et al. Comparison of the effects of an angiotensin-converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomised double blind study. J Hum Hypertens 1993; 7: 333–9 Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 1982; 285: 685–8 Parving H-H, Andersen AR, Smidt UM, et al. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983; I: 1175–8 Parving H-H, Andersen AR, Hommel E, et al. Effect of antihypertensive treatment on kidney function in insulin-dependent diabetic nephropathy. BMJ 1987; 294: 1443–7 Parving H-H, Andersen AR, Smidt UM, et al. Diabetic nephropathy and arterial hypertension: the effect of antihypertensive treatment. Diabetes 1983; 32 Suppl. 2: 83–7 Parving H-H, Andersen AR, Hommel E, et al. Effects of long-term antihypertensive treatment on kidney function in diabetic nephropathy. Hypertension 1985; 7 Suppl 2: 114–7 Parving H-H, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by captopril in insulin-dependent diabetics with nephropathy. BMJ 1988; 297: 1086–91 Baba T, Murabayashi S, Tomiyama T, et al. Uncontrolled hypertension is associated with a radipe progression of nephropathy in type II diabetic patients with proteinuria and presevered renal function. Tohoku J Exp Med 1990; 161: 311–8 Viberti GC. Outcome variables in the assessment of progression of diabetic kidney disease. Kidney Int 1994; 45 Suppl. 45: S121–4 Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–62 Hebert LA, Bain RP, Verme D, et al. Remission of nephrotic range proteinuria in type I diabetes. Kidney Int 1994; 46: 1688–93 Mogensen CE. Microalbuminuria predicts clinical proteinuira and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356–60 Hypertension in Diabetes Study Group. Hypertension in Diabetes Study (HDS): II. increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993; 11: 319–25 Sawicki PT, Heise T, Berger M. Antihypertensive treatment and mortality in diabetic patients: what is the evidence? Diabetologia 1997; 40: S134–7 Parving H-H, Hommel E. Prognosis in diabetic nephropathy. BMJ 1989; 99: 230–3 Mathiensen ER, Borch-Johnsen K, Jensen DV, et al. Improved survival in patients with diabetic nephropathy. Diabetologia 1989; 32: 884–6 Sawicki PT, Mühlhauser I, Didjurgeit U, et al. Intensified antihypertensive therapy is associated with improved survival in type 1 diabetic patients with nephropathy. J Hypertens 1995; 13: 933–8 Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645–52 Tatti P, Pahor M, Byington RP, et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21(4): 597–603 Hansson L, Hedner T, Lindholm LH, et al. The Captopril Prevention Project (CAPPP) in hypertension-Final results. J Hypertens 1989; 16 Suppl. 2: S22 Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998; 351: 1755–62 Kaplan N. J curve not burned off by HOT study. Lancet 1998; 351: 1748–9 Turner R, for theUK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13 Holman R, for the UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713–20 1999 World Health Organization. International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151–83 Passa P, Chatellier G, The Diab-Hycar Study Group. The Diab-Hycar Study. Diabetologia 1996; 39: 1662–7 Locatelli F, Alberti D, Graziani G, et al. Factors affecting chronic renal failure progression: results from a multicentre trial. Miner Electrolyte Metab 1992; 18: 295–302 ter Wee PM, Epstein M. Angiotensin-converting enzyme inhibitors and progression of nondiabetic chronic renal diseases. Arch Int Med 1993; 153: 1749–59 Zucchelli P, Zuccalà A. The diagnostic dilemma of hypertensive nephrosclerosis: the nephrologist’s view. Am J Kidney Dis 1993; 21 Suppl. 2: S87–91 Freedman BI, Iskandar SS, Appel RG. The link between hypertension and nephrosclerosis. Am J Kidney Dis 1995; 25: 207–21 Preston RA, Epstein M. Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease. J Hypertens 1997; 15: 1365–77 Fogo A, Breyer JA, Smith MC, et al. Accuracy of diagnosis of hypertensive nephrosclerosis in african americans: a report from the African Americans Study of Kidney Disease (AASK) Trial. Kidney Int 1997; 51: 244–52 Pedrinelli R. Microalbuminuria in hypertension. Nephron 1996; 73: 499–505 Ruilope LM. The kidney and cardiovascular risk. Nephrol Dial Transplant 1997; 12: 243–54 Bianchi S, Bigazzi R, Campese VM. Microalbuminuria in essential hypertension. J Nephrol 1997; 10: 216–8 Losito A, Fortunati F, Zampi I, et al. Impaired renal function reserve and albuminuria in essential hypertension. BMJ 1988; 296: 1562–4 Bigazzi R, Bianchi S, Baldari D, et al. Microalbuminuria in salt-sensitive patients: a marker for renal cardiovascular risk factors. Hypertension 1984; 23: 195–9 Mattei P, Arzilli F, Giovannetti R, et al. Microalbuminuria and renal haemodynamics in essential hypertension. Eur J Clin Invest 1997; 27: 755–60 Bianchi S, Bigazzi R, Baldari G, et al. Microalbuminuria in patients with essential hypertension: effects of an angiotensin converting enzyme inhibitor and of a calcium channel blocker. Am J Hypertens 1991; 4: 291–6 Erley CM, Haefele U, Heyne N, et al. Microalbuminuria in essential hypertension: reduction by different antihypertensive drugs. Hypertension 1993; 21: 810–5 Jensen JS, Borch-Johnsen K, Jensen G, et al. Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects. Clin Sci 1995; 88: 629–33 Puig JG, Mateos FA, Ramos TH, et al. Albumin excretion rate and metabolic modifications in patients with essential hypertension: effects of two angiotensin converting enzyme inhibitors. Am J Hypertens 1994; 7: 46–51 Agrawal B, Wolf K, Berger A, et al. Effects of antihypertensive treatment on qualitative estimates of microalbuminuria. J Hum Hypertens 1995; 10: 551–5 Sievert-Delle A, Ljungman S, Hartford M, et al. Effect of 14 years of antihypertensive treatment on renal function and urinary albumin excretion in primary hypertension. Am J Hypertens 1996; 9: 841–9 Ruilope LM, Alcazar JM Hernandez E, et al. Does an adequate control of blood pressure protect the kidney in essential hypertension? J Hypertens 1990; 8: 525–31 Vetter W, Wehling M, Foerster E-C, et al. Long-term effect of captopril on kidney function in various forms of hypertension. Klin Wochenschr 1984; 62: 731–7 Sanchez RA, Traballi CA, Marco EJ, et al. Effects of ACE inhibition on renal haemodynamics in essential hypertension and hypertension associated with chronic renal failure. Drugs 1991; 41 Suppl. 1: 25–30 Bauer JH, Reams GP, Lal SM. Renal protective effect of strict blood pressure control with enalapril therapy. Arch Intern Med 1987; 147: 1397–400 Salvetti A, Giovannetti R, Arrighi P, et al. How to treat the hypertensive patient with early renal damage. Am J Kidney Dis 1993; 21 Suppl. 2: 95–9 Himmelmann A, Hansson L, Hansson B-G, et al. ACE inhibition preserves renal function betterthan β-blockade in the treatment of essential hypertension. Blood Press 1995; 4: 85–90 Aurell M, Bengtsson C, Bjork S. Enalapril versus metoprolol in primary hypertension: effects on the glomerular filtration rate. Nephrol Dial Transplant 1997; 12: 2289–94 Pettinger WA, Lee HC, Reisch J, et al. Long-term improvement in renal function after short-term strict blood pressure control in hypertensive nephrosclerosis. Hypertension 1989; 13: 766–72 Toto RD, Mitchell HC, Smith RD, et al. ‘Strict’ blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int 1995; 48: 851–9 Pettinger WA, Mitchell HC, Lee HC, et al. Pseudo renal artery stenosis (PRAS) syndrome. Am J Hypertens 1989; 2: 349–51 Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939–45 246. Hall WD, Kusek JW, Kirk KA, et al. Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: the African-American Study of Kidney disease and hypertension pilot study. Am J Kidney Dis 1997; 29: 720–8 Rekola S, Bergstrand A, Bucht H. Deterioration rate in hypertensive IgA nephropathy: comparison of a converting enzyme inhibitor and β-blocking agent. Nephron 1991; 59: 57–60 Cattran DC, Greenwood C, Ritchie S. Long-term benefits of angiotensin-converting-enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: a comparison to patients reciving treatment with other antihypertensive agents and to patients reciving no therapy. Am J Kidney Dis 1994; 23: 247–54 Feriozzi S, Pierucci A, Roscia E, et al. Angiotensin converting enzyme inhibition delays the progression of chronic renal failure in hypertensive patients with immunoglobulin A nephropathy. J Hypertens 1989; 7 Suppl. 7: S63–4 Okamura M, Kanayama Y, Negoro N, et al. Long-term effects of calcium antagonists and angiotensin-converting enzyme inhibitors in patients with chronic renal failure of IgA nephropathy. In: Morii H, editor. Calcium regulating hormones. I. Role in disease and aging. Contrib Nephrol 1991; 90: 161–5 Bannister KM, Weaver A, Clarkson AR, et al. Effect of angiotensin converting enzyme and calcium channel inhibition on progression of IgA nephropathy. In: Clarkson AR, Woodroffe AJ, editors. IgA nephropathy: pathogenesis and treatment. Contrib Nephrol 1995; 111: 184–93 Rodicio JL, Alcazar JM, Ruilope LM. Influence of converting enzyme inhibition on glomerular filtration rate and proteinuria. Kidney Int 1990; 38: 590–4 Ritz E, Fliser D, Keller H, et al. Are newer antihypertensive agents really more effective than traditional drugs in progressive renal disease? Am J Kidney Dis 1991; 17 Suppl. 1: 76–80 Ferder LF, Inserra F, Daccordi H, et al. Enalapril improved renal function and proteinuria in chronic glomerulopathies. Nephron 1990; 55 Suppl. 1: 90–5 Kamper AL, Strangaard S, Leyssac PP. Effect of enalapril on the progression of chronic renal failure. A randomised controlled trial. Am J Hypertens 1992; 5: 423–30 Ambroso GC, Como G, Scalamogna A, et al. Treatment of arterial hypertension with nifedipine in patients with chronic renal insufficiency. Clin Nephrol 1985; 23: 41–5 Brazy PC, Fitzwilliam JF. Progressive renal disease: role of race and antihypertensive medications. Kidney Int 1990; 37: 1113–9 Eliahou HE, Cohen D, Hellberg B, et al. Effect of the calcium channel blocker nisoldipine on the progression of chronic renal failure in man. Am J Nephrol 1988; 8: 285–90 Bianchi S, Bigazzi R, Baldari G, et al. Long-term effects of enalapril and nicardipine on urinary albumin excretion in patients with chronic renal insufficiency: a 1-year follow-up. Am J Nephrol 1991; 11: 131–7 Zucchelli P, Zuccalà A, Borghi M, et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992; 42: 452–8 Hannedouche T, Landais P, Goldfarb B, et al. Randomised controlled trial of enalapril and β-blockers in non-diabetic chronic renal failure. BMJ 1994; 309: 833–7 vanEssen GG, Apperloo AJ, Rensma PL, et al. Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline? Kidney Int 1997; 52 Suppl. 63: S58–62 Ihle BU, Whitworth JA, Shahinfar S, et al. Angiotensin converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double blind trial. Am J Kidney Dis 1996; 27: 489–95 The GISEN group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997; 349: 1857–63 Cinotti GA, Zucchelli PC. Effect of lisinopril on the progression of non-diabetic chronic renal failure [abstract]. Nephrol Dial Transplant 1997; 12: A94 Locatelli F, Carbarns IRI, Maschio G, et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. Kidney Int 1997; 52 Suppl. 63: S63–6 Ruggenenti P, Perna A, Mosconi L, et al. for The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997; 349: 1857–63 Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med 1997; 127: 337–45 Maschio G. Protecting the residual renal function: how do ACE inhibitors and calcium antagonists compare. Nephron 1994; 67: 257–62 Navis G, de Zeeuw D, De Jong PE. ACE-inhibitors: panacea for progressive renal disease? Lancet 1997; 349(9069): 1852–3 Arrighi P, Giovannetti R, Mattei P, et al. Comparison of renal hemodynamic effects of four ACE-inhibitors in essential hypertensive patients. Blood Press 1995; 4: 236–41 Salvetti A, Argenio GF, Brogi G, et al. Management of hypertension and metabolic disorders. In: Kaplan NM, editor. Metabolic aspects of hypertension. London: Science Press, 1994; 6.1: 1–19 Teuscher AU, Weidmann PU. Requirements for antihypertensive therapy in diabetic patients: metabolic aspects. J Hypertens 1997; 15 Suppl. 2: S67–75